Form 4: ANI Pharma SVP Gutwerg Boosts Stake with Stock Award

ANI Pharmaceuticals SVP Ori Gutwerg received a restricted stock award of 12,969 shares and had 2,221 shares withheld for tax purposes.

Summary

• Ori Gutwerg, SVP, Generics at ANI Pharmaceuticals Inc. (ANIP), reported transactions involving the company's common stock.
• On February 26, 2026, Gutwerg acquired 12,969 shares of common stock at a price of $77.15 per share, as a restricted stock award.
• This restricted stock award will vest in four equal annual installments on the first, second, third, and fourth anniversaries of February 26, 2026.
• On February 28, 2026, 2,221 shares of common stock were disposed of at a price of $73.9 per share, withheld for tax purposes.
• The shares withheld for tax were in connection with the vesting of 4,342 previously reported restricted stock shares.
• Following these transactions, Gutwerg beneficially owns 86,842 shares of common stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. The acquisition of a significant restricted stock award by a senior executive indicates continued commitment and aligns management's interests with long-term company performance, despite the routine tax-related disposition.

Positives

• The acquisition of 12,969 shares through a restricted stock award demonstrates continued alignment of management's interests with shareholders.
• The grant of a restricted stock award is a common incentive for senior executives, indicating ongoing commitment to the company's performance.

Negatives

• A total of 2,221 shares were disposed of to cover tax obligations, resulting in a reduction of direct beneficial ownership.

Risks

• NA

Future Outlook

The restricted stock award granted on February 26, 2026, is scheduled to vest in four equal annual installments on the first, second, third, and fourth anniversaries of the grant date.

Industry Context

StockSavvy.ai notes that insider stock awards and subsequent tax-related dispositions are standard practices in executive compensation across various industries. This filing reflects a routine compensation event rather than a strategic market move.

Comparison to Industry Standards

• The use of restricted stock awards as a component of executive compensation is a common practice across the pharmaceutical industry and broader corporate landscape, aligning executive incentives with long-term shareholder value.
• The withholding of shares for tax purposes upon vesting is a standard, non-discretionary event for equity compensation, consistent with practices at comparable companies like Pfizer, Merck, or Johnson & Johnson when their executives receive similar awards.

Stakeholder Impact

• Shareholders: The restricted stock award aligns the interests of a key executive with long-term shareholder value, as the value of the award is tied to the company's stock performance.
• Employees: This filing pertains to executive compensation and does not directly impact the broader employee base, though it reflects standard compensation practices at the executive level.

Next Steps

• The restricted stock award will vest in four equal annual installments on the anniversaries of February 26, 2026.

Key Dates

Keywords

ANI Pharmaceuticals, ANIP, Ori Gutwerg, Insider Trading, Form 4, Restricted Stock Award, Stock Compensation, SVP Generics, Beneficial Ownership